Version 1
: Received: 24 July 2020 / Approved: 25 July 2020 / Online: 25 July 2020 (16:21:53 CEST)
Version 2
: Received: 21 October 2020 / Approved: 22 October 2020 / Online: 22 October 2020 (10:34:02 CEST)
Version 3
: Received: 5 December 2020 / Approved: 7 December 2020 / Online: 7 December 2020 (11:36:05 CET)
Karimzadeh, S.; Bhopal, R.; Nguyen Tien, H. Review of Infective Dose, Routes of Transmission and Outcome of COVID-19 Caused by the SARS-COV-2: Comparison with Other Respiratory Viruses. Epidemiology and Infection 2021, 149, doi:10.1017/s0950268821000790.
Karimzadeh, S.; Bhopal, R.; Nguyen Tien, H. Review of Infective Dose, Routes of Transmission and Outcome of COVID-19 Caused by the SARS-COV-2: Comparison with Other Respiratory Viruses. Epidemiology and Infection 2021, 149, doi:10.1017/s0950268821000790.
Karimzadeh, S.; Bhopal, R.; Nguyen Tien, H. Review of Infective Dose, Routes of Transmission and Outcome of COVID-19 Caused by the SARS-COV-2: Comparison with Other Respiratory Viruses. Epidemiology and Infection 2021, 149, doi:10.1017/s0950268821000790.
Karimzadeh, S.; Bhopal, R.; Nguyen Tien, H. Review of Infective Dose, Routes of Transmission and Outcome of COVID-19 Caused by the SARS-COV-2: Comparison with Other Respiratory Viruses. Epidemiology and Infection 2021, 149, doi:10.1017/s0950268821000790.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pandemic. Prevention and control strategies require an improved understanding of SARS-CoV-2 dynamics. We did a rapid review of the literature on SARS-CoV-2 viral dynamics with a focus on infective dose. We sought comparisons of SARS-CoV-2 with other respiratory viruses including SARS-CoV-1 and MERS-CoV. We examined laboratory animal, and human studies. The literature on infective dose, transmission, and routes of exposure was limited specially in humans, and varying endpoints were used for measurement of infection. We propose the minimum infective dose of COVID-19 in humans, is higher than 100 particles, possibly slightly lower than the 700 particles estimated for H1N1 influenza. Despite variability in animal studies, there was some evidence that increased dose at exposure correlated with higher viral load clinically, and severer symptoms. Higher viral load measures did not reflect COVID-19 severity. Aerosol transmission seemed to raise the risk of more severe respiratory complications in animals. An accurate quantitative estimate of the infective dose of SARS-CoV-2 in humans is not currently feasible and needs further research. Further work is also required on the relationship between routes of transmission, infective dose, co-infection, and outcomes.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received:
18 February 2021
Commenter:
Dr. S.J. Hasanain M.D.
The commenter has declared there is no conflict of interests.
Comment:
Dear professor Karmizadeh,
I enjoyed your excellent article regarding the infectivity of SARS COV2 and other resp. viruses. I am, also very impressed by the quality of research articles on virology from Iran. If a COVID 19 vaccine is being developed in Iran, I would suggest a direct challenge with either intra nasal or through SARS COV2 contaminated aerosol to the volunteers with adequate antibody response following their vaccination. The challenge dose would be calculated based on the TICD50 or the PFU as elegantly outlined in your article. There will be no need for a control group. This method should work with any vaccine platform equally well in less than 5 months.
Regards,
S.J.Hasanain
Commenter: Sedighe Karimzadeh
Commenter's Conflict of Interests: Author
Commenter: Dr. S.J. Hasanain M.D.
The commenter has declared there is no conflict of interests.
I enjoyed your excellent article regarding the infectivity of SARS COV2 and other resp. viruses. I am, also very impressed by the quality of research articles on virology from Iran. If a COVID 19 vaccine is being developed in Iran, I would suggest a direct challenge with either intra nasal or through SARS COV2 contaminated aerosol to the volunteers with adequate antibody response following their vaccination. The challenge dose would be calculated based on the TICD50 or the PFU as elegantly outlined in your article. There will be no need for a control group. This method should work with any vaccine platform equally well in less than 5 months.
Regards,
S.J.Hasanain